TrkB/C-induced HOXC6 activation enhances the ADAM8-mediated metastasis of chemoresistant colon cancer cells

Park,Ga Bin; Choi,Sangbong; Yoon,Yoo Sang; Kim,Daejin

doi:10.3892/mmr.2021.12062

TrkB/C-induced HOXC6 activation enhances the ADAM8-mediated metastasis of chemoresistant colon cancer cells

Authors:
- Ga Bin Park
- Sangbong Choi
- Yoo Sang Yoon
- Daejin Kim
View Affiliations

Affiliations: Department of Biochemistry, Kosin University College of Medicine, Busan 49267, Republic of Korea, Department of Internal Medicine, Division of Respirology, Sanggye Paik Hospital, Inje University College of Medicine, Seoul 01757, Republic of Korea, Department of Thoracic and Cardiovascular Surgery, Busan Paik Hospital, Inje University College of Medicine, Busan 47392, Republic of Korea, Department of Anatomy, Inje University College of Medicine, Busan 47392, Republic of Korea
Published online on: April 7, 2021 https://doi.org/10.3892/mmr.2021.12062
Article Number: 423

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The abnormal expression of tropomyosin receptor kinase (Trk) serves an important role in the promotion of cancer progression. Homeobox C6 (HOXC6) and A disintegrin and metalloproteinase domain‑containing 8 (ADAM8) are associated with the invasiveness of cancer cells. However, the exact relationship between these molecules and their downstream signaling pathways in chemoresistant colon cancer cells are largely unknown. Therefore, the current study investigated the association between TrkB/C with HOXC6 and ADAM8 in the induction of drug‑resistant colon cancer cell metastasis. The results demonstrated that chemoresistant colon cancer cells exhibited upregulated TrkB/C, HOXC6 and ADAM8 expression. Additionally, but also chemoresistant colon cancer cells demonstrated higher migratory activities compared with parent colon cancer cells. The pharmacological inhibition of TrkB/C activity reduced the phosphorylation of mitogen‑activated protein kinase kinase/ERK and subsequently suppressed HOXC6 and ADAM8 expression. In addition, gene silencing of HOXC6 inhibited ADAM8 and MMP activity, and inhibited the migration and invasion of drug‑resistant cancer cells. However, the targeted downregulation of ADAM8 using small interfering RNA failed to suppress TrkB/C‑associated ERK‑mediated HOXC6 signaling activity. Furthermore, pre‑treatment with ADAM10‑ and ADAM17‑specific inhibitors had no effect on attenuating the invasiveness of chemoresistant colon cancer cells. The results indicated that TrkB/C‑mediated ERK activation serves an important role in the metastasis of drug‑resistant colon cancer cells through the regulation of HOXC6/ADAM8 activity.

View Figures

View References

1	Chao MV: Neurotrophins and their receptors: A convergence point for many signalling pathways. Nat Rev Neurosci. 4:299–309. 2003. View Article : Google Scholar : PubMed/NCBI
2	Huang EJ and Reichardt LF: Neurotrophins: Roles in neuronal development and function. Annu Rev Neurosci. 24:677–736. 2001. View Article : Google Scholar : PubMed/NCBI
3	Douma S, Van Laar T, Zevenhoven J, Meuwissen R, Van Garderen E and Peeper DS: Suppression of anoikis and induction of metastasis by the neurotrophic receptor TrkB. Nature. 430:1034–1039. 2004. View Article : Google Scholar : PubMed/NCBI
4	Kupferman ME, Jiffar T, El-Naggar A, Yilmaz T, Zhou G, Xie T, Feng L, Wang J, Holsinger FC, Yu D, et al: TrkB induces EMT and has a key role in invasion of head and neck squamous cell carcinoma. Oncogene. 29:2047–2059. 2010. View Article : Google Scholar : PubMed/NCBI
5	Desmet CJ and Peeper DS: The neurotrophic receptor TrkB: A drug target in anti-cancer therapy? Cell Mol Life Sci. 63:755–759. 2006. View Article : Google Scholar : PubMed/NCBI
6	Yilmaz T, Jiffar T, de la Garza G, Lin H, Milas Z, Takahashi Y, Hanna E, MacIntyre T, Brown JL, Myers JN, et al: Theraputic targeting of Trk supresses tumor proliferation and enhances cisplatin activity in HNSCC. Cancer Biol Ther. 10:644–653. 2010. View Article : Google Scholar : PubMed/NCBI
7	Lee J, Jiffar T and Kupferman ME: A novel role for BDNF-TrkB in the regulation of chemotherapy resistance in head and neck squamous cell carcinoma. PLoS One. 7:e302462012. View Article : Google Scholar : PubMed/NCBI
8	Yu Y, Zhang S, Wang X, Yang Z and Ou G: Overexpression of TrkB promotes the progression of colon cancer. APMIS. 118:188–195. 2010. View Article : Google Scholar : PubMed/NCBI
9	Blondy S, Christou N, David V, Verdier M, Jauberteau MO, Mathonnet M and Perraud A: Neurotrophins and their involvement in digestive cancers. Cell Death Dis. 10:1232019. View Article : Google Scholar : PubMed/NCBI
10	Abate-Shen C: Deregulated homeobox gene expression in cancer: Cause or consequence? Nat Rev Cancer. 2:777–785. 2002. View Article : Google Scholar : PubMed/NCBI
11	Friedmann Y, Daniel CA, Strickland P and Daniel CW: Hox genes in normal and neoplastic mouse mammary gland. Cancer Res. 54:5981–5985. 1994.PubMed/NCBI
12	Bhatlekar S, Fields JZ and Boman BM: HOX genes and their role in the development of human cancers. J Mol Med (Berl). 92:811–823. 2014. View Article : Google Scholar : PubMed/NCBI
13	Bhatlekar S, Fields JZ and Boman BM: Role of HOX genes in stem cell differentiation and cancer. Stem Cells Int. 2018:35694932018. View Article : Google Scholar : PubMed/NCBI
14	Chang SL, Chan TC, Chen TJ, Lee SW, Lin LC and Win KT: HOXC6 overexpression is associated with Ki-67 expression and poor survival in NPC patients. J Cancer. 8:1647–1654. 2017. View Article : Google Scholar : PubMed/NCBI
15	Ramachandran S, Liu P, Young AN, Yin-Goen Q, Lim SD, Laycock N, Amin MB, Carney JK, Marshall FF, Petros JA, et al: Loss of HOXC6 expression induces apoptosis in prostate cancer cells. Oncogene. 24:188–198. 2005. View Article : Google Scholar : PubMed/NCBI
16	Yang P, Kang W, Pan Y, Zhao X and Duan L: Overexpression of HOXC6 promotes cell proliferation and migration via MAPK signaling and predicts a poor prognosis in glioblastoma. Cancer Manag Res. 11:8167–8179. 2019. View Article : Google Scholar : PubMed/NCBI
17	Ji M, Feng Q, He G, Yang L, Tang W, Lao X, Zhu D, Lin Q, Xu P, Wei Y, et al: Silencing homeobox C6 inhibits colorectal cancer cell proliferation. Oncotarget. 7:29216–29227. 2016. View Article : Google Scholar : PubMed/NCBI
18	Kim KJ, Moon SM, Kim SA, Kang KW, Yoon JH and Ahn SG: Transcriptional regulation of MDR-1 by HOXC6 in multidrug-resistant cells. Oncogene. 32:3339–3349. 2013. View Article : Google Scholar : PubMed/NCBI
19	Reiss K and Saftig P: The ‘a disintegrin and metalloprotease’ (ADAM) family of sheddases: Physiological and cellular functions. Semin Cell Dev Biol. 20:126–137. 2009. View Article : Google Scholar : PubMed/NCBI
20	Gavert N, Sheffer M, Raveh S, Spaderna S, Shtutman M, Brabletz T, Barany F, Paty P, Notterman D, Domany E, et al: Expression of L1-CAM and ADAM10 in human colon cancer cells induces metastasis. Cancer Res. 67:7703–7712. 2007. View Article : Google Scholar : PubMed/NCBI
21	Park GB and Kim D: TLR4-mediated galectin-1 production triggers epithelial-mesenchymal transition in colon cancer cells through ADAM10- and ADAM17-associated lactate production. Mol Cell Biochem. 425:191–202. 2017. View Article : Google Scholar : PubMed/NCBI
22	Ishikawa N, Daigo Y, Yasui W, Inai K, Nishimura H, Tsuchiya E, Kohno N and Nakamura Y: ADAM8 as a novel serological and histochemical marker for lung cancer. Clin Cancer Res. 10:8363–8370. 2004. View Article : Google Scholar : PubMed/NCBI
23	Wildeboer D, Naus S, Amy Sang QX, Bartsch JW and Pagenstecher A: Metalloproteinase disintegrins ADAM8 and ADAM19 are highly regulated in human primary brain tumors and their expression levels and activities are associated with invasiveness. J Neuropathol Exp Neurol. 65:516–527. 2006. View Article : Google Scholar : PubMed/NCBI
24	Romagnoli M, Mineva ND, Polmear M, Conrad C, Srinivasan S, Loussouarn D, Barillé-Nion S, Georgakoudi I, Dagg Á, McDermott EW, et al: ADAM8 expression in invasive breast cancer promotes tumor dissemination and metastasis. EMBO Mol Med. 6:278–294. 2014. View Article : Google Scholar : PubMed/NCBI
25	Conrad C, Götte M, Schlomann U, Roessler M, Pagenstecher A, Anderson P, Preston J, Pruessmeyer J, Ludwig A, Li R, et al: ADAM8 expression in breast cancer derived brain metastases: Functional implications on MMP-9 expression and transendothelial migration in breast cancer cells. Int J Cancer. 142:779–791. 2018. View Article : Google Scholar : PubMed/NCBI
26	Yang Z, Bai Y, Huo L, Chen H, Huang J, Li J, Fan X, Yang Z, Wang L and Wang J: Expression of A disintegrin and metalloprotease 8 is associated with cell growth and poor survival in colorectal cancer. BMC Cancer. 14:5682014. View Article : Google Scholar : PubMed/NCBI
27	Meng L, Liu B, Ji R, Jiang X, Yan X and Xin Y: Targeting the BDNF/TrkB pathway for the treatment of tumors. Oncol Lett. 17:2031–2039. 2019.PubMed/NCBI
28	Schlomann U, Koller G, Conrad C, Ferdous T, Golfi P, Garcia AM, Höfling S, Parsons M, Costa P, Soper R, et al: ADAM8 as a drug target in pancreatic cancer. Nat Commun. 6:61752015. View Article : Google Scholar : PubMed/NCBI
29	Park GB, Jeong JY and Kim D: Modified TLR-mediated downregulation of miR-125b-5p enhances CD248 (endosialin)-induced metastasis and drug resistance in colorectal cancer cells. Mol Carcinog. 59:154–167. 2020. View Article : Google Scholar : PubMed/NCBI
30	Gomez DR, Byers LA, Nilsson M, Diao L, Wang J, Li L, Tong P, Hofstad M, Saigal B, Wistuba I, et al: Integrative proteomic and transcriptomic analysis provides evidence for TrkB (NTRK2) as a therapeutic target in combination with tyrosine kinase inhibitors for non-small cell lung cancer. Oncotarget. 9:14268–14284. 2018. View Article : Google Scholar : PubMed/NCBI
31	Chen SW, Zhang Q, Xu ZF, Wang HP, Shi Y, Xu F, Zhang WJ, Wang P and Li Y: HOXC6 promotes gastric cancer cell invasion by upregulating the expression of MMP9. Mol Med Rep. 14:3261–3268. 2016. View Article : Google Scholar : PubMed/NCBI
32	Wang DD, Xu Y, Tu YL, Tan XL, Zhu ZM, Han MM, Dou CQ, Zeng JP, Tan JW, Du JD, et al: Comparison analysis in synchronous and metachronous metastatic colorectal cancer based on microarray expression profile. Hepatogastroenterology. 61:2215–2218. 2014.PubMed/NCBI
33	Contreras-Zárate MJ, Day NL, Ormond DR, Borges VF, Tobet S, Gril B, Steeg PS and Cittelly DM: Estradiol induces BDNF/TrkB signaling in triple-negative breast cancer to promote brain metastases. Oncogene. 38:4685–4699. 2019. View Article : Google Scholar
34	Meldolesi J: Neurotrophin Trk receptors: New targets for cancer therapy. Rev Physiol Biochem Pharmacol. 174:67–79. 2018. View Article : Google Scholar : PubMed/NCBI
35	Watanabe Y, Saito M, Saito K, Matsumoto Y, Kanke Y, Onozawa H, Hayase S, Sakamoto W, Ishigame T, Momma T, et al: Upregulated HOXA9 expression is associated with lymph node metastasis in colorectal cancer. Oncol Lett. 15:2756–2762. 2018.PubMed/NCBI
36	López-Otín C and Hunter T: The regulatory crosstalk between kinases and proteases in cancer. Nat Rev Cancer. 10:278–292. 2010. View Article : Google Scholar
37	Mason SD and Joyce JA: Proteolytic networks in cancer. Trends Cell Biol. 21:228–237. 2011. View Article : Google Scholar : PubMed/NCBI
38	Fu L, Liu N, Han Y, Xie C, Li Q and Wang E: ADAM10 regulates proliferation, invasion, and chemoresistance of bladder cancer cells. Tumour Biol. 35:9263–9268. 2014. View Article : Google Scholar : PubMed/NCBI
39	Wang XJ, Feng CW and Li M: ADAM17 mediates hypoxia-induced drug resistance in hepatocellular carcinoma cells through activation of EGFR/PI3K/Akt pathway. Mol Cell Biochem. 380:57–66. 2013. View Article : Google Scholar : PubMed/NCBI
40	Park GB, Chung YH and Kim D: 2-Deoxy-D-glucose suppresses the migration and reverses the drug resistance of colon cancer cells through ADAM expression regulation. Anticancer Drugs. 28:410–420. 2017. View Article : Google Scholar : PubMed/NCBI